Company intelligence / Profile preview

Fore Genomics

Ownership: Private
Development stage: Commercial

Overview

Fore Genomics offers a commercially available, physician-approved whole genome sequencing service for newborns and children. Their FORESITE 360 test screens for over 300–800+ pediatric-onset genetic conditions and provides pharmacogenomic insights on more than 100 medications. Results are delivered with access to board-certified genetic counselors, enabling early detection of actionable health risks and personalized care plans. The service is CLIA/CAP-accredited, with ongoing annual reanalysis as new discoveries emerge.

Therapeutic areas: OtherRare Diseases
Modalities: Diagnostic testWhole genome sequencing (WGS)
Industry: Molecular Diagnostics

Partnerships

Inocras (partnership for WGS & bioinformatics platform enhancement)

Beyond the preview

Go deeper on Fore Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fore Genomics.

Explore the full profile